PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 145 products for "PD-1/PD-L1".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Penpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Purity:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.14 kDaSintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.Purity:> 95% - >95.0% (SDS-PAGE); 95.0% (SEC-HPLC)Color and Shape:LiquidMolecular weight:143.78 kDaZimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Purity:95%Color and Shape:Transparent LiquidMolecular weight:146.54 kDaAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purity:95.07% - 99.29%Color and Shape:White SolidMolecular weight:3321.61Durvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purity:95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146.03 kDaBMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purity:97.36%Color and Shape:SolidMolecular weight:631.11Ref: TM-T10565
1mg52.00€5mg120.00€1mL*10mM (DMSO)169.00€10mg187.00€25mg380.00€50mg612.00€100mg973.00€200mg1,305.00€Budigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.Purity:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.72 kDaDostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purity:>95%Color and Shape:Transparent LiquidMolecular weight:144.18 kDaTislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Purity:95.07%Color and Shape:Transparent LiquidMolecular weight:145 kDaEzabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Purity:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Color and Shape:LiquidMolecular weight:145.21 kDaSpartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purity:SDS-PAGE:95.2%;SEC-HPLC:96.3%Color and Shape:Transparent LiquidMolecular weight:145.74 kDaManelimab
CAS:Manelimab is an IL-10Ra-activating immunocytokine that exerts potent anti-inflammatory and immunomodulatory effects by mimicking the IL-10 signaling pathway.Color and Shape:LiquidTQB-2858
TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).Color and Shape:Odour LiquidAnti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.Color and Shape:Odour LiquidTobemstomig
CAS:Tobemstomig is a bispecific antibody targeting PD-1 and LAG-3, designed to enhance T cell activation. By blocking these immune checkpoints, it can promote cytotoxic T cell responses and exhibits potential antitumor activity. [Molecular weight 145.24 kDa.]Acrixolimab
CAS:Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].Purity:98%Color and Shape:LiquidOpamtistomig
CAS:Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.Color and Shape:LiquidPD-1/PD-L1-IN-49
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.Formula:C27H32N4O5Color and Shape:SolidMolecular weight:492.567Rilvegostomig
CAS:Rilvegostomig is a bispecific humanized IgG1 antibody targeting the immune-regulating receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT). It enhances T cell activation, fostering a robust anti-tumor immune response, especially in cancers such as non-small cell lung cancer (NSCLC). Molecular weight: 146.06 KD.Sotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurity:98%Color and Shape:Solid
